Health
LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint – News-Medical.Net
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by…
(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer.
Dr. Jay M. Lee, chief, Division of Thoracic Surgery at Ronald Reagan UCLA Medical Center in Los Angeles, today reported on results…
-
Noosa News19 hours agoAustralian chocolate gains a competitive edge in global cocoa shortage
-
General22 hours agoBudget billions helps cashed-up state lead debt battle
-
General21 hours agoHawthorn’s AFLW star Tilly Lucas-Rodd undergoes gender affirming top surgery
-
Noosa News12 hours agoInvestigations underway after dead body found on Townsville road